Journal Article
. 2018 Aug; 9(1):3348.
doi: 10.1038/s41467-018-05566-x.

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

Brett Schrand 1 Emily Clark 1 Agata Levay 1 Ailem Rabasa Capote 1 Olivier Martinez 1 Randall Brenneman 1 Iris Castro 1 Eli Gilboa 2 
  • PMID: 30135425
  •     54 References
  •     2 citations


Uptake of tumor antigens by tumor-infiltrating dendritic cells is limiting step in the induction of tumor immunity, which can be mediated through Fc receptor (FcR) triggering by antibody-coated tumor cells. Here we describe an approach to potentiate tumor immunity whereby hapten-specific polyclonal antibodies are recruited to tumors by coating tumor cells with the hapten. Vaccination of mice against dinitrophenol (DNP) followed by systemic administration of DNP targeted to tumors by conjugation to a VEGF or osteopontin aptamer elicits potent FcR dependent, T cell mediated, antitumor immunity. Recruitment of αGal-specific antibodies, the most abundant naturally occurring antibodies in human serum, inhibits tumor growth in mice treated with a VEGF aptamer-αGal hapten conjugate, and recruits antibodies from human serum to human tumor biopsies of distinct origin. Thus, treatment with αGal hapten conjugated to broad-spectrum tumor targeting ligands could enhance the susceptibility of a broad range of tumors to immune elimination.

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
Xiaojuan Liu, Yang Pu, +7 authors, Meng Michelle Xu.
Nat Med, 2015 Sep 01; 21(10). PMID: 26322579    Free PMC article.
Highly Cited.
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.
Mark P Chao, Irving L Weissman, Ravindra Majeti.
Curr Opin Immunol, 2012 Feb 09; 24(2). PMID: 22310103    Free PMC article.
Highly Cited. Review.
Fcγ receptor pathways during active and passive immunization.
Stylianos Bournazos, Jeffrey V Ravetch.
Immunol Rev, 2015 Oct 27; 268(1). PMID: 26497515    Free PMC article.
Mouse and human FcR effector functions.
Pierre Bruhns, Friederike Jönsson.
Immunol Rev, 2015 Oct 27; 268(1). PMID: 26497511
Highly Cited. Review.
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.
David J DiLillo, Jeffrey V Ravetch.
Cancer Immunol Res, 2015 Jul 04; 3(7). PMID: 26138698
Highly Cited. Review.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Rony Dahan, Emanuela Sega, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2015 Sep 17; 28(3). PMID: 26373277
Highly Cited.
Immune complex-mediated antigen presentation induces tumor immunity.
Khadija Rafiq, Amy Bergtold, Raphael Clynes.
J Clin Invest, 2002 Jul 03; 110(1). PMID: 12093890    Free PMC article.
Type I and type II Fc receptors regulate innate and adaptive immunity.
Andrew Pincetic, Stylianos Bournazos, +5 authors, Jeffrey V Ravetch.
Nat Immunol, 2014 Jul 22; 15(8). PMID: 25045879    Free PMC article.
Highly Cited. Review.
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
Kavita M Dhodapkar, Joseph Krasovsky, Barbara Williamson, Madhav V Dhodapkar.
J Exp Med, 2002 Jan 10; 195(1). PMID: 11781371    Free PMC article.
Highly Cited.
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
Danita H Schuurhuis, Nadine van Montfoort, +6 authors, Ferry Ossendorp.
J Immunol, 2006 Apr 06; 176(8). PMID: 16585547
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
David J DiLillo, Jeffrey V Ravetch.
Cell, 2015 May 16; 161(5). PMID: 25976835    Free PMC article.
Highly Cited.
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.
Shannon P Hilchey, Ollivier Hyrien, +7 authors, Steven H Bernstein.
Blood, 2009 Feb 07; 113(16). PMID: 19196657    Free PMC article.
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
L W Kwak, M J Campbell, +3 authors, R Levy.
N Engl J Med, 1992 Oct 22; 327(17). PMID: 1406793
Highly Cited.
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Clare Taylor, Dawn Hershman, +8 authors, Raphael Clynes.
Clin Cancer Res, 2007 Sep 06; 13(17). PMID: 17785568
Modulating IgG effector function by Fc glycan engineering.
Tiezheng Li, David J DiLillo, +3 authors, Lai-Xi Wang.
Proc Natl Acad Sci U S A, 2017 Mar 16; 114(13). PMID: 28289219    Free PMC article.
Highly Cited.
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
E Reali, J W Greiner, +5 authors, A G Siccardi.
Cancer Res, 2001 Jul 17; 61(14). PMID: 11454701
Cutting Edge: IgE Plays an Active Role in Tumor Immunosurveillance in Mice.
Elisa A Nigro, Anna T Brini, +9 authors, Luca Vangelista.
J Immunol, 2016 Aug 28; 197(7). PMID: 27566822
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors.
Yingjuan Lu, Philip S Low.
Cancer Immunol Immunother, 2002 Apr 10; 51(3). PMID: 11941454
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.
Yaron Carmi, Matthew H Spitzer, +9 authors, Edgar G Engleman.
Nature, 2015 Apr 30; 521(7550). PMID: 25924063    Free PMC article.
Highly Cited.
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
Fernando Pastor, Despina Kolonias, James O McNamara, Eli Gilboa.
Mol Ther, 2011 Aug 11; 19(10). PMID: 21829171    Free PMC article.
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Brett Schrand, Alexey Berezhnoy, +7 authors, Eli Gilboa.
Cancer Immunol Res, 2014 Jun 19; 2(9). PMID: 24938283    Free PMC article.
VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.
T Cohen, H Gitay-Goren, +4 authors, G Neufeld.
J Biol Chem, 1995 May 12; 270(19). PMID: 7744769
Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival.
D C Darland, L J Massingham, +3 authors, P A D'Amore.
Dev Biol, 2003 Nov 19; 264(1). PMID: 14623248
Highly Cited.
Secretion of VEGF-165 has unique characteristics, including shedding from the plasma membrane.
Maria Luisa Guzmán-Hernández, Gael Potter, +2 authors, Tamas Balla.
Mol Biol Cell, 2014 Feb 07; 25(7). PMID: 24501421    Free PMC article.
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.
Ratchada Cressey, Onusa Wattananupong, Nirush Lertprasertsuke, Usanee Vinitketkumnuen.
BMC Cancer, 2005 Oct 06; 5. PMID: 16202150    Free PMC article.
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.
Fernando Pastor, Despina Kolonias, Paloma H Giangrande, Eli Gilboa.
Nature, 2010 May 14; 465(7295). PMID: 20463739    Free PMC article.
Highly Cited.
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.
Paula J Bates, Damian A Laber, +2 authors, John O Trent.
Exp Mol Pathol, 2009 May 21; 86(3). PMID: 19454272    Free PMC article.
Highly Cited. Review.
Classical Flt3L-dependent dendritic cells control immunity to protein vaccine.
Niroshana Anandasabapathy, Rachel Feder, +15 authors, Ralph M Steinman.
J Exp Med, 2014 Aug 20; 211(9). PMID: 25135299    Free PMC article.
In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.
Fumiyoshi Okano, Miriam Merad, Katsuyoshi Furumoto, Edgar G Engleman.
J Immunol, 2005 Feb 25; 174(5). PMID: 15728471
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, +19 authors, Miriam Merad.
Immunity, 2016 Apr 21; 44(4). PMID: 27096321    Free PMC article.
Highly Cited.
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Matthew H Spitzer, Yaron Carmi, +10 authors, Edgar G Engleman.
Cell, 2017 Jan 24; 168(3). PMID: 28111070    Free PMC article.
Highly Cited.
CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
Katherine A Murphy, Jami R Erickson, +6 authors, John R Ohlfest.
J Immunol, 2013 Dec 03; 192(1). PMID: 24293627    Free PMC article.
The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.
Bruce A Macher, Uri Galili.
Biochim Biophys Acta, 2007 Dec 01; 1780(2). PMID: 18047841    Free PMC article.
Highly Cited. Review.
Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse.
A D Thall, P Malý, J B Lowe.
J Biol Chem, 1995 Sep 15; 270(37). PMID: 7545161
Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.
D C LaTemple, U Galili.
Xenotransplantation, 1998 Dec 16; 5(3). PMID: 9741457
Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
D C LaTemple, J T Abrams, S Y Zhang, U Galili.
Cancer Res, 1999 Jul 23; 59(14). PMID: 10416604
Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection.
E Gorelik, L Duty, F Anaraki, U Galili.
Cancer Res, 1995 Sep 15; 55(18). PMID: 7545089
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties.
G Poste, J Doll, I R Hart, I J Fidler.
Cancer Res, 1980 May 01; 40(5). PMID: 7370995
Highly Cited.
Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
Uri Galili, Kim Wigglesworth, Ussama M Abdel-Motal.
J Immunol, 2007 Mar 21; 178(7). PMID: 17372027
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.
Brett Schrand, Bhavna Verma, +8 authors, Adrian Ishkanian.
Cancer Res, 2017 Jan 14; 77(6). PMID: 28082399    Free PMC article.
Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability.
F R Miller, B E Miller, G H Heppner.
Invasion Metastasis, 1983 Jan 01; 3(1). PMID: 6677618
Highly Cited.
Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Elisa A Nigro, Anna T Brini, +4 authors, Luca Vangelista.
J Immunol, 2009 Sep 15; 183(7). PMID: 19748979
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Marion G Ott, Frederik Marmé, +6 authors, Diane Seimetz.
Int J Cancer, 2011 Jun 28; 130(9). PMID: 21702044    Free PMC article.
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.
Riad Abès, Emmanuelle Gélizé, Wolf Herman Fridman, Jean-Luc Teillaud.
Blood, 2010 May 05; 116(6). PMID: 20439625
Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.
A Sala, I Gresser, +7 authors, F Belardelli.
Cancer Res, 1992 May 15; 52(10). PMID: 1581903
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy.
Jiehua Zhou, John J Rossi.
Mol Ther Nucleic Acids, 2014 Jun 18; 3. PMID: 24936916    Free PMC article.
Highly Cited.
The role of Osteopontin in tumor metastasis.
Philip Y Wai, Paul C Kuo.
J Surg Res, 2004 Oct 27; 121(2). PMID: 15501463
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.
Zhiyong Mi, Hongtao Guo, +3 authors, Paul C Kuo.
Mol Ther, 2008 Nov 06; 17(1). PMID: 18985031    Free PMC article.
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Shawn E Lupold, Brian J Hicke, Yun Lin, Donald S Coffey.
Cancer Res, 2002 Jul 19; 62(14). PMID: 12124337
Highly Cited.
Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.
Ussama M Abdel-Motal, Kim Wigglesworth, Uri Galili.
Cancer Immunol Immunother, 2009 Feb 03; 58(10). PMID: 19184002    Free PMC article.
Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies.
Enrique Gómez Alcaide, Sinduya Krishnarajah, Fabian Junker.
Vaccines (Basel), 2021 May 01; 9(4). PMID: 33924183    Free PMC article.
Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer.
Silvia Achilli, Nathalie Berthet, Olivier Renaudet.
RSC Chem Biol, 2021 Jul 03; 2(3). PMID: 34212148    Free PMC article.